Loading
MIMETAS
MIMETAS makes plates of tiny channels in which human cells grow with a flowing fluid supply, a small working model of tissue known as an organ-on-a-chip. Its cancer models let researchers watch whether immune cells, including CAR-T cells, can reach a tumour and kill it.
Overview
MIMETAS was founded in 2013 in Leiden, the Netherlands, and Gaithersburg, Maryland, by Paul Vulto and Jos Joore, who are co-chief executives, and has offices in the Netherlands, the United States and Japan. Its OrganoPlate, which the company calls the first mass-produced, quality-controlled organ-on-a-chip platform, holds perfused 3D human tissue models. Its oncology models are 3D tumour models in a perfused system that include infiltrating lymphocytes; the company describes uses in modelling T-cell trafficking into tumours for T-cell engagers, CAR-T extravasation, migration and tumour killing, immune suppression in co-cultures with M2 macrophages and fibroblasts, a 1,537-compound screen in an angiogenic sprouting model, and combination therapy screening in hepatocellular carcinoma.
Notes
- Ownership and financing are not stated on the pages read. Headquarters is given as Leiden, one of the two founding sites; the company does not name a headquarters. companyType cro-services is the corpus's nearest category for a platform and model-services provider.
Connected
4cancers
fronts
technologies
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
mimetas.com · 3
A source that has moved or gone is reported by the weekly link check. /audit/